Cardiorenal Syndrome in Western Countries: Epidemiology, Diagnosis and Management Approaches

Ronco, Claudio; Lullo, Luca Di

doi:10.1159/000448749

Cited by 54 publications

(55 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While many factors can be involved in the etiology of the disease, such as atherosclerosis, hypertension, stroke and coronary artery disease, the general consequence is blood vessel dysfunction or heart failure [78]. Heart failure occurs when the heart is unable to pump sufficient blood to the body and it is associated with a progressive and considerable loss of cardiomyocytes [79]. Loss of competent CPCs in chronic ischemic cardiomyopathy may underlie terminal heart failure [80].…”

Section: Stem Cell Behavior In Different Diseasesmentioning

confidence: 99%

Unhealthy Stem Cells: When Health Conditions Upset Stem Cell Properties

Pérez

Lucas

Gálvez

2018

Cell Physiol Biochem

View full text Add to dashboard Cite

The stem cell field has grown very rapidly during the last decade, offering the promise of innovative therapies to treat disease. Different stem cell populations have been isolated from various human adult tissues, mainly from bone marrow and adipose tissue, but many other body tissues harbor a stem cell population. Adult tissue stem cells are invariably found in discrete microenvironments termed niches, where they play key roles in tissue homeostasis by enabling lifelong optimization of organ form and function. Some diseases are known to strike at the stem cell population, through alterations in their specific microenvironments, making them non-viable. Furthermore, it has been shown that a transformed stem cell population could prompt the development of certain cancers. This review focuses on the potential negative aspects of a range of diseases on the activity of stem cells and how their potential use in cell therapies may be affected.

show abstract

Section: Stem Cell Behavior In Different Diseasesmentioning

confidence: 99%

Unhealthy Stem Cells: When Health Conditions Upset Stem Cell Properties

Pérez

Lucas

Gálvez

2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…CRS Type 1 (CRS1) is characterized by worsening of cardiac function [eg, acute heart failure (AHF)], resulting in acute kidney injury (AKI) [2]. Nearly 25-44% of AHF patients would develop CRS1 during their hospitalization, which is closely associated with longer hospitalization, increased risk of readmission, morbidity and mortality, and substantial loss of quality of life [3][4][5][6][7]. The adverse clinical outcomes make the identification of patients at high risk for developing CRS1 very critical.…”

Section: Introductionmentioning

confidence: 99%

Nomogram Model to Predict Cardiorenal Syndrome Type 1 in Patients with Acute Heart Failure

Fan

Yang

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Cardiorenal syndrome type 1(CRS1) is a serious clinical condition in patients with acute heart failure (AHF) associated with adverse clinical outcomes. Although several biomarkers for identifying CRS1 have been reported, early and accurate predicting CRS1 still remains a challenge. This study was aimed to develop and validate an individualized predictive nomogram for the risk of CRS1 in patients with AHF. Methods: A total of 1235 AHF patients between 2013 and 2018 were included in this study. The patients were randomly classified into training set (n=823) and validation set (n=412). All data of the training set were used to screen the predictors of CRS1 via univariate and multivariate analyses. A nomogram was developed based on these predictors and validated by internal and external validation. The nomogram validation comprised discriminative ability determined by the area under the curve (AUC) of receiver-operating characteristic (ROC) curve and the predictive accuracy by calibration plots. Results: The overall incidence of CRS1 was 31.7%. Multivariate logistic regression revealed that age, diabetes, NYHA class, eGFR, hs-CRP and uAGT were independently associated with CRS1. A nomogram developed based on the six variables was with the AUC 0.885 and 0.823 on internal and external validation, respectively. Calibration plots showed that the predicted and actual CRS1 probabilities were fitted well on both internal and external validation. Conclusion: The proposed nomogram could predict the individualized risk of CRS1 with good accuracy, high discrimination, and potential clinical applicability in patients with AHF.

show abstract

“…Patients with acute and/or chronic HF [39, 40], especially when complicated by renal insufficiency, frequently present difficult volume management problems. The coexistence of both heart and renal failure makes these patients particularly difficult to manage, and a small change in intravascular volume status can lead to a large change in overall clinical condition.…”

Section: Discussionmentioning

confidence: 99%

A Novel Fluorescent Clinical Method to Rapidly Quantify Plasma Volume

Molitoris¹,

George²,

Murray³

et al. 2019

Cardiorenal Med

View full text Add to dashboard Cite

Objectives: To determine the performance of a rapid fluorescent indicator technique for measuring plasma volume (PV). Methods: This was an open-label, observational evaluation of a two-component intravenous visible fluorescent dye technique to rapidly measure PV in 16 healthy subjects and 16 subjects with chronic kidney disease (8 stage 3 and 8 stage 4 CKD), at 2 clinical research sites. The method consisted of a single intravenous injection of 12 mg of a large 150-kDa carboxy-methyl dextran conjugated to a fluorescent rhodamine-derived dye as the PV marker (PVM), and 35 mg of a small 5-kDa carboxy-methyl dextran conjugated to fluorescein, the renal clearance marker. Dye concentrations were quantified 15 min after the injections for initial PV measurements using the indicator-dilution principle. Additional samples were taken over 8 h to evaluate the stability of the PVM as a determinant of PV. Blood volumes (BV) were calculated based on PV and the subject’s hematocrit. Pharmacokinetic parameters were calculated from the plasma concentration data taken over several days using noncompartmental methods (Phoenix WinNonlin®). Linear correlation and Bland-Altman plots were used to compare visible fluorescent injectate-measured PV compared to Nadler’s formula for estimating PV. Finally, 8 healthy subjects received 350 mL infusion of a 5% albumin solution in normal saline over 30 min and a repeat PV determination was then carried out. Results: PV and BV varied according to weight and body surface area, with PV ranging from 2,115 to 6,234 mL and 28.6 to 41.9 mL/kg when weight adjusted. Both parameters were stable for > 6 h with repeated plasma measurements of the PVM. There was no difference between healthy subjects and CKD subjects. Overall, there was general agreement with Nadler’s estimation formula for the mean PV in subjects. A 24-h repeat dose measurement in 8 healthy subjects showed PV variability of 98 ± 121 mL (mean = 3.8%). Additionally, following an intravenous bolus of 350 mL of a 5% albumin solution in normal saline in 8 healthy subjects, the mean (SD) measured increase in PV was 356 (±50.0) mL post-infusion. There were no serious adverse events reported during the study. Conclusions: This minimally invasive fluorescent dye approach safely allowed for rapid, accurate, and reproducible determination of PV, BV, and dynamic monitoring of changes following fluid administration.

show abstract

Cardiorenal Syndrome in Western Countries: Epidemiology, Diagnosis and Management Approaches

Cited by 54 publications

References 66 publications

Unhealthy Stem Cells: When Health Conditions Upset Stem Cell Properties

Unhealthy Stem Cells: When Health Conditions Upset Stem Cell Properties

Nomogram Model to Predict Cardiorenal Syndrome Type 1 in Patients with Acute Heart Failure

A Novel Fluorescent Clinical Method to Rapidly Quantify Plasma Volume

Contact Info

Product

Resources

About